Asymmetry Capital Management

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 2
Average round size
info
The average size of a deal this fund participated in
$72M
Portfolio companies 2
Rounds per year 0.20
Lead investments 0
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Medical Device
  • Medical
  • Health Diagnostics
  • Health Care

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Asymmetry Capital Management:
Typical Co-investors
Asymmetry Capital Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Asymmetry Capital Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Cape Capital AG Switzerland, Zürich, Zurich
Central Banking Corporation -
Eight Roads Ventures India Bangalore, India, Karnataka
Fujiansheng DianziXinxi Canye Guquan Touzi China, Foochow, Fujian
Fullerton Financial Holdings Central Region, Singapore, Singapore
Global Infrastructure Partners (GIP) New York, New York, United States
Hedef Filo Istanbul, Kagithane, Turkey
Ignite Farm California, United States, Walnut Creek
Impact First Investments Herzliya, Israel, Tel Aviv
Junhe Capital China, Shanghai
Montcalm Capital California, San Francisco, United States
Ningbo Angel Capital Guiding Fund China, Ningbo, Zhejiang
PSS Systems California, Mountain View, United States
Quality Jobs Fund (QJF) -
S4 Holdings -
Service Corp International Houston, Texas, United States
Shenzhen Investment Holdings China, Futian, Guangdong
Snowpoint Ventures California, San Francisco, United States
University of Manitoba Canada, Manitoba, Winnipeg
VC4A Amsterdam, Noord-Holland, The Netherlands

News
DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Asymmetry Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: